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of cognitive decline. Our aim was to assess whether risk of stroke in mid life is associated with cog-
nitive decline over 10 years of follow-up.
Methods: We studied 4153 men and 1657 women (mean age, 55.6 years at baseline) from theWhite-
hall II study, a longitudinal British cohort study. We used the Framingham Stroke Risk Profile
(FSRP), which incorporates age, sex, systolic blood pressure, diabetes mellitus, smoking, prior car-
diovascular disease, atrial fibrillation, left ventricular hypertrophy, and use of antihypertensive med-
ication. Cognitive tests included reasoning, memory, verbal fluency, and vocabulary assessed three
times over 10 years. Longitudinal associations between FSRP and its components were tested using
mixed-effects models, and rates of cognitive change over 10 years were estimated.
Results: Higher stroke risk was associated with faster decline in verbal fluency, vocabulary, and
global cognition. For example, for global cognition there was a greater decline in the highest
FSRP quartile (20.25 of a standard deviation; 95% confidence interval: 20.28 to20.21) compared
with the lowest risk quartile (P5 .03). No association was observed for memory and reasoning. Of the
individual components of FSRP, only diabetes mellitus was associated independently with faster
cognitive decline (b 5 20.06; 95% confidence interval, 20.01 to 0.003; P 5 .03).
Conclusion: Elevated stroke risk at midlife is associated with accelerated cognitive decline over 10
years. Aggregation of risk factors may be especially important in this association.
 2013 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
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Stroke increases the risk of dementia considerably [1–4].
In community-based studies, the prevalence of poststroke
dementia in stroke survivors is about 30% and the incidence
of new onset dementia after stroke increases from 7% after
1 year to 48% after 25 years [5]. Cognitive impairment is
three times more common in people who have had a stroke
than in those who have not [6]. Even in the absence ofthor. Tel.:133 (0)1 77 74 74 06; Fax:133 (0)1 77 74
ra.kaffashian@inserm.fr
e Authors. Published by Elsevier Inc. on behalf of the Alzh
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6/j.jalz.2012.07.001stroke, individuals with a high risk of stroke have substan-
tially higher cognitive deficits [7]. Individual risk factors
such as obesity, hypertension, hypercholesterolemia, and
smoking that predispose to stroke have been linked to ad-
verse structural brain changes, cognitive impairment, and
dementia [8–17]. Moreover, there is evidence that
vascular risk factors predispose one to both vascular
dementia and Alzheimer’s disease [5,18]. The clustering
of risk factors may be particularly important and may
increase the risk of cognitive impairment in an additive or
synergistic manner, setting individuals on a trajectory of
cognitive decline in advance of clinically detectable
symptoms of cognitive impairment and dementia [16].eimer’s Association. This is an open access article under the CC BY-NC-ND
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of cardiovascular disease, both coronary heart disease
and stroke, recommend use of multifactorial risk prediction
models. These risk scores offer an effective evaluation
of vascular risk particularly in younger populations, in
which the prevalence of stroke is low, but risk of stroke
may nevertheless be present as a result of the accumulation
of low to moderate risk of multiple risk factors for stroke.
Identification of associations of subclinical vascular risk
with cognitive decline at the “brain at risk” stage is im-
portant and provides a great opportunity for prevention
[19,20].
The Framingham risk scores are among the most widely
validated and commonly used risk algorithms in clinical and
research settings. However, their utility for predicting cogni-
tive deficits in relation to vascular risk has remained rela-
tively unexplored. The Framingham Stroke Risk Profile
(FSRP) uses routinely measured risk factors to estimate
10-year risk of stroke. A number of studies have examined
the relation of the FSRP in predicting cognitive deficits.
The FSRP has been shown to be associated with incident
cognitive impairment [21] and worse performance on vari-
ous cognitive tests such as delayed verbal memory, verbal
fluency [22], and abstract reasoning [7]. However, the few
studies that have examined FSRP in relation to cognition
are either limited by their cross-sectional design [7,22,23];
were conducted in a small, select population [24]; or had
a short follow-up and used a single-item measure of cogni-
tive status [21].
We sought to examine the association between stroke risk
and longitudinal change in cognitive test scores using three
repeated cognitive measures over a 10-year period in a large
sample of middle-aged individuals.2. Methods
2.1. Study population
TheWhitehall II study was established in 1985 on 10,308
London-based office staff (6895 men and 3413 women). De-
tails of the cohort and its follow-up have been described pre-
viously [25]. Briefly, all office staff aged 35 to 55 years in 20
civil service departments in London, UK, were invited to par-
ticipate. In total, 73% of those invited agreed to participate in
phase 1 (1985–1988), which consisted of a clinical examina-
tion and a self-administered questionnaire. Clinical examina-
tion included measures of blood pressure, anthropometry,
biochemistry, neuroendocrine function, and subclinical
markers of cardiovascular disease. Subsequent phases of
data collection have alternated between a questionnaire-
alone phase and a questionnaire accompanied by clinical ex-
amination. Cognitive testingwas introduced to the full cohort
during phase 5 (1997–1999) and was repeated during phase 7
(2002–2004) and phase 9 (2007–2009). All participants pro-
vided informed consent; the University College London
ethics committee approved the study.2.2. Assessment of Framingham Stroke Risk Profile
The FSRP is a clinical risk score that is used to calculate
a sex-specific 10-year probability of stroke for individuals
who are free of stroke at baseline. The original algorithm
is based on prediction of 427 stroke events observed
throughout a 10-year follow-up period for 2372 men and
3362 women in the Framingham Heart Study. The FSRP is
based on the following risk factors: age, sex, systolic blood
pressure, antihypertensive medication, diabetes, cigarette
smoking status, history of cardiovascular disease, atrial fi-
brillation, and left ventricular hypertrophy as determined
by electrocardiogram [26,27]. The FSRP has been shown
to predict strongly the incidence of stroke in our cohort [28].
We drew risk score components from questionnaire and
clinical examination data at phase 5 (1997–199) in those
free of stroke. Blood pressure was taken twice in the sitting
position with a Hawksley random-zero sphygmomanometer
after a 5-minute rest (Lynjay Services Ltd.,Worthing, United
Kingdom). The average of the two readings was used in the
analysis. Antihypertensive medication included diuretics,
beta blockers, angiotensin-converting enzyme inhibitors,
and calcium channel blockers. Diabetes was defined by
a fasting glucose level of  7.0 mmol/L, a 2-hour postload
glucose level of  11.1 mmol/L, reported doctor-diagnosed
diabetes, or use of diabetes medication [29]. Participants
were categorized with respect to cigarette smoking status
as current smokers or past/nonsmokers. History of cardio-
vascular disease was based on clinical examination at phases
1, 3, or 5 (via electrocardiograms and angiograms) and cor-
roborated records obtained from general practitioners or
hospitals. The diagnosis of atrial fibrillation and left ventric-
ular hypertrophy was made using a standard 12-lead electro-
cardiogram and the Minnesota code classification system
for electrocardiographic findings (atrial fibrillation, code
3-1 for High Amplitude R-waves; left ventricular hypertro-
phy, code 8-3-1 for Arrhythmias). The stroke risk profile ex-
pressed as a predicted 10-year probability of incident stroke
(measured as a percentage), was computed using beta coef-
ficients based on the Cox proportional hazards regression
model in the Framingham study [26,27].2.3. Assessment of cognitive function
The cognitive test battery consisted of five standard tasks
to assess performance in various cognitive domains. In our
cohort, these tests were shown to be sensitive to detecting
small changes in cognitive function over time in participants
as young as 45 to 49 years of age [30].
The Alice Heim 4-I is composed of a series of 65 verbal
and mathematical reasoning items of increasing difficulty
[31]. It tests inductive reasoning, measuring the ability to
identify patterns and infer principles and rules. The time al-
lowed for this test was 10 minutes. Short-term verbal mem-
ory was assessed with a 20-word free recall test. Participants
were presented a list of 20 one- or two-syllable words at
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as many of the words in any order, and they had 2 minutes to
do so.
We used two measures of verbal fluency: phonemic and
semantic. Phonemic fluency was assessed via “S” words
and semantic fluency via “animal” words [32]. Participants
were asked to recall in writing as many words beginning
with “S” and as many animal names as they could. One min-
ute was allowed for each test. Vocabulary was assessed using
the Mill Hill Vocabulary test, used in its multiple-choice for-
mat, consisting of a list of 33 stimulus words ordered by in-
creasing difficulty and six response choices [33]. In addition,
a global cognitive score was created using all five of these
tests by first standardizing raw scores on each test to z scores
(mean, 0; standard deviation (SD), 1) using the baseline
mean and SD value in the entire cohort for each test. Z scores
were then averaged to yield the global cognitive score.2.4. Covariates
Our analyses were adjusted for important demographic
and health-related factors, including age, sex, ethnicity, ed-
ucation, depressive symptoms, physical activity, and alcohol
use. Although age and sex are both components of the FSRP,
we included them as covariates because of their established
association with cognitive function. Age was centered at the
mean value for the analytical sample. Ethnicity was catego-
rized into (i) white and (ii) other ethnic groups. Education
was measured as highest level of education achieved. Cate-
gories included (i) elementary or lower secondary, (ii) higher
secondary (A’ levels), and (iii) first university degree or
higher. We also assessed the effect of occupational position,
classified as administrative, professional or executive, and
clerical or supportive position. We also adjusted the analyses
for depressive symptoms and health behaviors that in our co-
hort were shown to be associated with cognitive outcomes
[34,35]. Depressive symptoms were assessed using the
four-item depression subscale of the General Health Ques-
tionnaire and had two categories (0–3 and4). Alcohol con-
sumption was assessed using questions on the number of
alcoholic drinks consumed during the past 7 days. This in-
formation was divided into “measures” of spirits, “glasses”
of wine, and “pints” of beer, and was converted to number
of units of alcohol, with each unit corresponding to 8 g eth-
anol. For example, a standard measure of spirits and a glass
of wine are considered to contain 8 g alcohol, and a pint of
beer, 16 g alcohol. Participants’ alcohol consumption was
categorized as follows: none (0 unit/week), moderate
(1–14 units/week for women and 1–21 units/week for
men), and heavy (.14 units/week for women and .21
units/week for men). Physical activity level was determined
from phase 5 questionnaires that included 20 items on fre-
quency and duration of participation in different leisure-
time physical activities (e.g., walking, general housework,
cycling, sports) that were used to compute hours per week
of each intensity level. Physical activity level was catego-rized as follows: high, more than 2.5 hours/week of moder-
ate or more than 1 hour/week of vigorous physical activity;
moderate, between 1 hour/week and 2.5 hours/week of mod-
erate physical activity; and low, less than 1 hour/week of
moderate and less than 1 hour/week of vigorous physical
activity.2.5. Statistical analysis
For ease of interpretation, we categorized stroke risk into
quartiles, with the first quartile representing lowest risk and
the fourth quartile representing highest stroke risk. To allow
comparability of the five cognitive tests, they were standard-
ized to z scores, as described previously.
We used linear mixed-effects models to estimate 10-year
decline and associated 95% confidence intervals (CI) in each
of the five measures of cognitive function. This method uses
all available data over the 10 year follow-up, including those
with one or two missing cognitive tests, and takes into ac-
count the intraindividual correlation inherent in repeated
measures. In our models, fixed effects included terms for
time, the main effect term for each variable (stroke risk,
age, sex, ethnicity, education, depressive symptoms, physi-
cal activity, and alcohol use), and interactions between
time and each variable. The interaction between a given vari-
able and time represents the effect of that variable on change
in cognitive score over time. In addition to these main ef-
fects, two random effects were included—one for the inter-
cept and one for the slope.
The stroke risk! time! sex interaction did not suggest
sex differences in the rate of cognitive decline; thus, our
analyses were not stratified by sex. Our final models ad-
justed for demographic factors included terms for FSRP
quartile, time, age, sex, ethnicity, and education, and the in-
teraction between time and each of FSRP quartile, age, sex,
ethnicity, and education. An interaction term for FSRP quar-
tile and age was also included. Additional models included
terms for the demographics-adjusted models plus physical
activity, alcohol use, and depressive symptoms, and their in-
teraction with time. The low stroke risk quartile was used as
the referent category to obtain P values for the difference in
cognitive change in the remaining three quartiles. We con-
ducted supplementary analyses to explore further each
FSRP component as an independent risk factor for cognitive
decline.
We also undertook sensitivity analyses to test the robust-
ness of our main findings. We modeled the association
between FSRP and cognitive decline, taking FSRP as a con-
tinuous variable, to represent a broader range of stroke risk.
We carried out the same analyses as outlined earlier on log-
transformed FSRP scores. We also conducted additional
analyses to account for interim events (e.g., incident stroke)
and missing cognitive function data in our analyses, and
tested for the interaction with APOE 34 carrier status (de-
fined as presence or absence of1 APOE 34 allele) in a sub-
set of the study population with these data (n 5 4936).
Table 1
Characteristics of the study sample (phase 5, 1997–1999)
Variable Data
S. Kaffashian et al. / Alzheimer’s & Dementia 9 (2013) 572–579 575Analyses were performed using Proc Mixed procedure in
SAS software (version 9; SAS Institute Inc., Cary, NC,
USA).Framingham Stroke Risk Profile (FSRP), mean (SD) 4.5 (3.5)
FSRP components
Age, y, mean (SD) 55.6 (6.0)
Men, n (%) 4153 (71.5)
Systolic blood pressure, mmHg, mean (SD) 123.0 (16.4)
Antihypertensive medications, n (%) 733 (12.6)
Diabetes, n (%) 225 (3.9)
Current smoker, n (%) 563 (9.7)
History of CVD, n (%) 331 (5.7)
Atrial fibrillation, n (%) 29 (0.5)
Left ventricular hypertrophy, n (%) 290 (5.0)
Covariates
Education, n (%)
Lower primary/secondary 2554 (43.9)
A levels 1522 (26.2)
University 1734 (29.8)
White ethnicity, n (%) 5370 (92.4)
Depressive symptoms, n (%) 716 (12.3)
Alcohol use, n (%)
None 871 (14.9)
Moderate 3522 (60.6)
Heavy 1417 (24.4)
Physical activity, n (%)
Low 1737 (29.9)
Moderate 975 (16.8)
High 3098 (53.3)
Abbreviations: CVD, cardiovascular disease; SD, standard deviation.
Fig. 1. Mean cognitive test scores at phase 5 by Framingham Stroke Risk
Profile (FSRP) quartile. Q1, Q2, Q3, and Q4, quartiles 1 through 4, respec-
tively.3. Results
Of 10,308 participants at the inception of the Whitehall II
study (1985–1988), 7830 (75.9%) participated in phase 5
(1997–1999), the baseline of the current analysis. We in-
cluded participants for whom stroke risk could be calculated
at phase 5 and who had at least one cognitive test measure
during the follow-up (n 5 6118). Our analysis is based on
5810 individuals (4153 men and 1657 women), after exclud-
ing participants with prevalent stroke (n5 48) or those miss-
ing data for covariates (n 5 260); 73% of participants had
complete data at all three phases and 20.2% at two phases.
Restricting the analyses to participants with complete data
at all three phases did not change our results significantly.
Compared with individuals not included in these analyses,
our sample included individuals who were younger (55.6
years vs. 57.5 years at phase 5, P, .001) and more educated
(28.0% vs. 15% with a university degree, P, .001). Among
participants who had at least one cognitive measure over
three waves, those with data at all three waves were different
from those with data at one or two waves; they had a lower
FSRP (4.3% vs. 5.1%, P , .001), were younger (55.2 years
vs. 56.7 years, P , .001), and were primarily men (72% vs.
67%, P , .001). There was also a higher proportion of indi-
viduals with a university education (29.8% vs. 24.9%, P ,
.01). Mean FSRP in our analytical sample was 4.5% (SD,
3.5%; range, 1%–78%). Detailed characteristics of the study
population are presented in Table 1 (see Supplementary
Table 1 for quartile-specific characteristics).
Mean cognitive test scores (z scores) at baseline (phase 5)
by FSRP quartile are presented in Fig. 1. Persons in the high-
est stroke risk quartile had lower mean cognitive test scores
compared with those in the lowest risk quartile, and there
was a negative trend in cognitive test scores across the
four stroke risk groups (P for trend5 .001 on all tests except
vocabulary, when P 5 .07).
Estimates of 10-year change in cognitive z scores as
a function of stroke risk at baseline are presented in
Table 2. In models adjusted for demographic factors, in-
creased stroke risk was associated with faster cognitive de-
cline for verbal fluency, vocabulary, and global cognition.
For example, compared with a decline of 20.32 SD unit
per 10 years in phonemic fluency test, for persons in the low-
est stroke risk quartile, cognitive decline was 20.39 SD
(95% CI, 20.46 to 20.32) and 20.41 SD (95% CI, 20.48
to20.34) over 10 years for those in the third and fourth quar-
tile, respectively. Similarly, in models adjusted for demo-
graphic and health-related factors, those in the fourth
FSRP quartile showed faster decline in verbal fluency,
vocabulary, and global cognition. Compared with the lowest
stroke risk quartile, there was a 0.04-SD unit faster decline in
global cognition in the fourth stroke risk quartile comparedwith the lowest risk quartile (P 5 .03). These differences
were evident only when comparing the fourth quartile
(FSRP  6%) with the lowest risk referent quartile. Adjust-
ing associations for occupation, an indicator of socioeco-
nomic status (instead of education), did not change the
results considerably.
We investigated further individual FSRP components as
independent risk factors for cognitive decline over 10 years,
relating each of the FSRP components to global cognitive
function. In models adjusted for demographics and health-
related factors, only diabetes (b 5 2 0.06; 95% CI, 20.01
Table 2
Cognitive change as a function of stroke risk (FSRP)
Cognitive tests
10-Year cognitive change (95% CI) per FSRP quartile
1 (mean, 2.4%) 2 (mean, 4.0%) 3 (mean, 5.0%) 4 (mean, 9.3%)
Adjusted for demographics
Reasoning 20.31 (20.34, 20.28) 20.30 (20.34, 20.26) 20.33 (20.38, 20.29) 20.33 (20.37, 20.29)
Memory 20.23 (20.29, 20.17) 20.18 (20.26, 20.10) 20.23 (20.32, 20.14) 20.20 (20.24, 20.08)
Phonemic fluency 20.32 (20.37, 20.27) 20.34 (20.40, 20.28) 20.39 (20.46, 20.32) 20.41 (20.48, 20.34)*
Semantic fluency 20.22 (20.27, 20.17) 20.26 (20.33, 20.22) 20.26 (20.33, 20.19) 20.30 (20.36, 20.24)*
Vocabulary 0.05 (0.02, 0.08) 0.06 (0.02, 0.09) 0.03 (20.004, 0.08) 20.008 (20.04, 0.03)y
Global cognition 20.21 (20.23, 20.18) 20.21 (20.23, 20.18) 20.23 (20.26, 20.21) 20.24 (20.27, 20.21)*
Adjusted for demographics and health related factors
Reasoning 20.33 (20.36, 20.29) 20.32 (20.36, 20.28) 20.35 (20.40, 20.30) 20.35 (20.40, 20.30)
Memory 20.25 (20.32, 20.18) 20.20 (20.28, 20.12) 20.25 (20.34, 20.16) 20.18 (20.27, 20.009)
Phonemic fluency 20.33 (20.39, 20.27) 20.34 (20.41, 20.28) 20.39 (20.47, 20.32) 20.42 (20.48, 20.13)*
Semantic fluency 20.21 (20.27, 20.16) 20.27 (20.33, 20.20) 20.25 (20.32, 20.18) 20.29 (20.36, 20.22)*
Vocabulary 0.04 (0.01, 0.08) 0.05 (0.01, 0.09) 0.03 (0.01, 0.08) 20.01 (20.05, 0.03)y
Global cognition 20.21 (20.24, 20.19) 20.16 (20.24, 20.18) 20.24 (20.27, 20.20) 20.25 (20.28, 20.21)*
Abbreviations: CI, confidence interval; FSRP, Framingham Stroke Risk Profile.
NOTE. Estimates derived from linear mixed models using three assessments over 10 years. Models adjusted for demographics include age centered at the
mean, sex, ethnicity, and education. Health-related factors include depressive symptoms, physical activity, and alcohol consumption.
*P , .05, difference in mean cognitive change compared with referent quartile 1.
yP , .01, difference in mean cognitive change compared with referent quartile 1.
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versely with decline in global cognition over 10 years
(Table 3).
Last, we obtained similar results in analyses of stroke risk
as a continuous variable. Here, too, verbal fluency, vocabu-
lary, and global cognition were associated with cognitive de-
cline over 10 years (see Supplementary Table 2). Other
sensitivity analyses to test the robustness of our results indi-
cated that accounting for interim stroke events (n5 146) did
not influence the findings greatly. Restricting the analyses to
participants with complete cognitive data at all three phases
(n5 4258) did not alter the results qualitatively. In addition,
the association between 10-year risk of stroke and cognitive
decline was not modified by APOE 34 status.4. Discussion
In this large cohort of middle-aged men and women, we
found higher risk of stroke to be associated with fasterTable 3
Association of vascular risk factor components of the Framingham Stroke Risk P
Risk factor
10-Year change in global cognition
Adjusted for demographics
b 95 % CI P val
SBP 20.01 (20.04, 0.02) .39
Diabetes 20.04 (20.10, 0.003) .05
Smoking 20.03 (20.07, 0.003) .07
History of CVD 0.002 (20.04, 0.05) .93
AF 20.05 (20.22, 0.12) .53
LVH 20.04 (20.08, 0.003) .08
Abbreviations: AF, atrial fibrillation; CI, confidence interval; CVD, cardiovascu
NOTE. Estimates derived from linear mixed models using three assessments ov
mean, sex, ethnicity, and education. Health-related factors include depressive symdecline in multiple cognitive domains assessed using a bat-
tery of cognitive tests administered three times over 10
years. There was faster decline in phonemic and semantic
fluency, vocabulary, and global cognition in the highest
risk quartile compared with the referent lowest risk quartile.
Our study, based on longitudinal data, provides a less biased
estimate of the causal association between stroke risk and
cognitive decline than cross-sectional data. The relationship
between vascular risk factors and cognition is likely to be bi-
directional; cross-sectional data on elderly subjects do not
allow the direction of the association to be established. In
this study, we addressed whether stroke risk in mid life,
when stroke is rare, is associated with more rapid cognitive
decline. Our findings add to the literature linking vascular
risk to cognitive impairment by providing evidence for the
association between stroke risk in mid life and long-term
cognitive decline. Using the FSRP as an aggregate measure
of risk factors, we found that mid to low risk levels on more
than one component of the stroke risk score can lead torofile and cognitive change
Adjusted for demographic and health related factors
ue b 95 % CI P value
20.01 (20.04, 0.02) .41
20.06 (20.10, 20.003) .03
20.03 (20.07, 0.003) .08
0.001 (20.04, 0.05) .94
20.07 (20.20, 0.11) .54
20.04 (20.08, 20.0004) .05
lar disease; LVH, left ventricular hypertrophy; SBP, systolic blood pressure.
er 10 years. Models adjusted for demographics include age centered at the
ptoms, physical activity, and alcohol consumption.
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found that, even in our relatively low-risk middle-aged pop-
ulation, this led to a detectable decline in cognitive perfor-
mance over 10 years. Although our data do not allow us to
determine an exact cutoff for stroke risk that clearly confers
a greater risk of cognitive decline, we observed a faster rate
of cognitive decline only in the highest risk quartile (FSRP
6%; mean, 9.3%) compared with the referent lowest risk
quartile. Thus, it appears that in our study sample a stroke
risk 6% is associated with more rapid cognitive decline.
Among individual risk factors, only diabetes was associ-
ated independently with cognitive decline. Although this as-
sociation has not been found in some studies [21], the
observed relation between diabetes and cognitive decline
in our study is supported by a number of studies reporting as-
sociations of diabetes with longitudinal changes onmagnetic
resonance imaging markers of vascular brain injury [17], in-
cident cognitive impairment and cognitive decline
[13,36,37], and incident dementia [38]. There is compelling
evidence for a causal relationship between alterations in gly-
cemic control and subsequent brain ischemic and atrophic
changes [39]. Although the absence of an independent asso-
ciation between other risk factors for stroke and cognitive
decline may be related to study population attributes (e.g.,
lower prevalence of risk factors in the current study), it
can also substantiate the suggestion that the combined influ-
ence or clustering of these risk factors may be particularly
important in this association. Indeed, stroke risk factors
are correlated highly with each other. Overall, it appears
that FSRP is a good predictor of cognitive impairment and
cognitive decline. Our findings support further the notion
that stroke risk factors begin to exert their influence on cog-
nition early and that they may act in an additive manner in
affecting cognitive decline. Furthermore, although in our
study the differences in rate of cognitive decline between
risk groups may seem small, they are nonetheless important
from a pathogenetic stand point, especially considering that
the mean age in our population at stroke risk assessment was
only 55 years.
Although the neuropsychological tests used in various
studies are not identical, it appears that stroke risk com-
monly assessed using the FSRP is associated with cognitive
function in multiple cognitive domains [7,22–24]. We found
that higher stroke risk was associated with decline in all
cognitive domains except memory and reasoning. A 3-year
follow-up study of 235 healthy older men showed an associ-
ation between FSRP and decline only on verbal fluency; no
associations between FSRP and decline in memory or vi-
sual–spatial function were reported [24]. In contrast, in
a study of 23,752 stroke-free individuals monitored for an
average of 4 years, a higher FSRP was found to be related
to incident cognitive impairment in global cognitive func-
tion that focused on memory [21]. Several studies suggest
that vascular disease does not always affect memory, and
that vascular risk factors may have a particularly detrimental
effect on frontally mediated cognitive functions such as ver-bal fluency [13,40,41]. Deficits in executive function have
long been recognized as a salient feature of cognitive
impairment of vascular origin. In relation to FSRP, at least
three other cross-sectional studies report similar associations
between stroke risk and cognitive function. Elias et al. [7] re-
ported associations between higher FSRP and deficits in
multiple domains, including abstract reasoning and visual–
spatial memory, but not verbal memory, in 2175 participants
of the Framingham Offspring Study. Seshadri et al. [23]
found similar associations between FSRP and visual–spatial
and executive function, but not with verbal memory. These
results conflict with another study that found an association
between FSRP and both immediate and delayed verbal
memory, and semantic verbal fluency [22]. However, it is
important to note that the comparison of our findings with
these studies is limited because of important differences in
study methods, particularly their cross-sectional design.
The mechanisms underlying the association between
vascular risk factors and cognitive function remain to be
elucidated fully. However, studies suggest that subclinical
cerebrovascular disease may present an important link
between major risk factors for stroke and cognitive func-
tion. These mechanisms include silent cerebral infarctions,
brain atrophy, and white matter abnormalities [23,42–44].
Hypertension in mid life is associated with accelerated
white matter hypterintensity volume (WMHV); diabetes
and smoking are linked to a more rapid increase in
temporal horn volume, which is a surrogate marker of
accelerated hippocampal atrophy. Smoking has also been
linked to a marked decrease in total brain volume [17].
The presence of silent brain infarcts on magnetic resonance
imaging is associated with worse performance on neuro-
psychological tests and a steeper decline in global cogni-
tive function, memory performance, and psychomotor
speed [43].
The strengths of our study include its large sample size,
three cognitive measures over 10 years to study longitudi-
nal cognitive decline, and use of a representative battery
of cognitive tests, permitting examination of different and
distinct aspects of cognition. However, there are several
limitations. First, because Whitehall II participants were
office-based staff, they may not be representative of the
British population, thus potentially limiting the generaliz-
ability of our findings. Second, it is possible that observed
associations between stroke risk and cognitive decline are
underestimations because our study sample included par-
ticipants with a more favorable demographic and stroke
risk profile than those excluded from the analysis and the
general population.
In conclusion, the observed associations between an ele-
vated risk of stroke and long-term cognitive decline in mul-
tiple cognitive domains have important implications. Our
findings provide some evidence that an aggregation of vas-
cular risk is especially important in this association, and sug-
gest that vascular risk assessment may be better determined
using a multifactorial risk score. That this association is
S. Kaffashian et al. / Alzheimer’s & Dementia 9 (2013) 572–579578evident in a relatively young population indicates early neu-
rological consequences of vascular risk factors leading to
cognitive decline. Public health implications are in the do-
main of early prevention and treatment of stroke risk factors
in middle age to reduce or forestall cognitive decline and de-
mentia. Dementia is characterized by a long preclinical
phase; individuals who develop dementia later may show
subtle cognitive changes as early as two decades before di-
agnosis [45]. Currently, there are no specific treatments for
cognitive impairment or dementia. Given the important vas-
cular contribution to cognitive impairment, detection and
treatment of risk factors particularly at mid life may be
most effective in the prevention or progression of cognitive
impairment. Indeed, recent projections suggest that as many
as half of the cases of Alzheimer’s disease might be pre-
vented by risk factor reduction and could potentially prevent
up to 3 million cases of Alzheimer’s disease worldwide [46].Acknowledgments
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